for 2 successive days, repeated 4 times within 4 weeks). The remaining patients, with reduced BMD, were randomly assigned to either MPPT without alendronate (10 women, 2 men, aged 47 ±1.0 year, group B) or MPPT with concomitant alendronate 10 mg given orally every day within 4 weeks (18 women, 3 men, aged 47 ±1.0 year, group C). The characteristics of the patients are presented in TAbLE 1.
In patients with GO, the biochemical markers of bone metabolism, serum calcium (Ca) and potassium (P) levels, and urinary Ca excretion were assessed twice: in groups A and B before and after MPPT; in group C before and after MPPT with concomitant alendronate therapy. In healthy controls, the tests were performed only once. In all subjects, thyroid-stimulating hormone (TSH), FT 3 , and FT 4 levels were assessed once (in patients with GO before treatment).
The following markers of bone formation were determined: serum osteocalcin, carboxyterminal propeptide of type I collagen (PICP), total alkaline phosphatase (tAP), bone alkaline phosphatase (bAP). Moreover, the following markers of bone resorption were assessed: carboxyterminal telopeptide of type I collagen (ICTP) and urinary deoxypiridinoline (DPD) excretion. Another marker of bone resorption, serum cross-linked C-terminal telopeptide of type I collagen (CTX), was additionally measured in group C and in controls.
TSH was assessed by immunoradiometric assay (IRMA; Orion Diagnostica, Czech Republic); FT 4 and FT 3 by a radioimmunoassay (RIA; Immunotech, Czech Republic); serum TSH-receptor antibodies (TRAbs) by a radio receptor assay (B.R.A.H.M.S. Diagnostica, Germany); osteocalcin by RIA (B.R.A.H.M.S. Diagnostica); PICP and ICTP by RIA (Orion Diagnostica, Finland); bAP by IRMA (OSTASE Beckman Coulter kit, United States); urinary DPD excretion by an enzyme linked inmunosorbent assay (ELISA; Pyrilinks-D, Metra Biosystems, Inc., United States) and the final results were expressed as nmol DPD/ mmol creatinine [Cr]); CTX was determined by ELISA (Serum Cross laps TM kit Osteomer Biotech A/S, Denmark).
The normal ranges were as follows: FT 4 , 11.5-23.0 pmol/l; FT 3 , 2.5-5.8 pmol/l; serum TRAbs, <9.0 U/l; osteocalcin, 0.67-2.01 nmol/l; PICP: women, 50-170 μg/l; men, 38-202 μg/l; ICTP: women, 1.6-5.0 μg/l; men, 1.3-5.2 μg/l; bAP: women, 8.7 ±2.9 μg/l; men, 12.3 ±4.3 μg/l; urinary DPD excretion: women, 2.5-6.5 nmol/ mmol Cr; men, 2.5-5.5 nmol/nmol/mmol Cr; CTX: women, 2304 ±110 pmol/l; men, 2382 ±1364 pmol/l. Serum Ca, P, and tAP levels and urinary Ca excretion (mmol/10 mmol Cr/24 h) were assessed by standard methods in the Central Hospital Laboratory.
statistical analysis All results were expressed as means ± standard error of the mean. The mean values were compared using the t test (for parameters pulse therapy (MPPT) seems to be more effective than treatment with prednisone alone. 8, 9 Hyperthyroidism, either associated with or preceding the development of GO, might adversely affect bone tissue.
10 Optimal ophthalmopathy treatment should not induce further bone resorption.
The aim of the current study was, first, to investigate the effect of high-dose MPPT on bone metabolism in patients with active and moderately severe GO; second, to determine whether the effect of MPPT on bone turnover is different in patients with normal and reduced bone mineral density (BMD); and, third, to determine whether the combination of MPPT and alendronate treatment could prevent the possible unfavorable effect of MPPT on bone metabolism in patients with reduced BMD.
PATIENTs ANd mEThOds Fifty-three euthyroid patients with active and moderately severe GO and 20 sex-and age-matched healthy controls were included in the study. Patients with GO were selected from among consecutive patients admitted between January 2006 and September 2010 to the Department of Internal Diseases, Meidcal University of Silesia, Katowice, Poland.
The diagnosis of ophthalmopathy was based on ophthalmological investigation and quantitative magnetic resonance imaging of the orbits and retro-orbital space. Activity of GO was defined with the clinical activity score of 4 or higher, based on the classification system proposed by Mourits et al. 11 Severity of GO was assessed using the NOSPECS classification by calculating the total eye score. 12 All patients were clinically euthyroid, with normal free triiodothyronine (FT 3 ) and free thyroxine (FT 4 ) levels during the study and within 4 months prior to the study. Subjects with hyperthyroidism were maintained euthyroid with thionamide therapy. All female subjects were premenopausal. The exclusion criteria were as follows: contraindications to glucocorticoid therapy, previous treatment with glucocorticoids, or any other current therapy known to affect bone or calcium metabolism. The study was approved by the Local Bioethics Committee and was conducted in accordance with the Helsinki Declaration. Informed consent was obtained from all subjects.
BMD of the lumbar spine and femoral neck was assessed using dual energy X-ray absorptiometry (DEXA) before treatment. BMD values were expressed as g per cm³. The obtained results were compared with those of sex-matched young controls at peak bone mass and expressed as T-scores. According to the definition of the World Health Organization, 13 osteopenia was diagnosed in patients with the T-score between <-1 to -2. 5 standard deviation (SD), osteoporosis in those with the T-score <-2. 5, and normal bone density in those with the T-score not exceeding 1 SD below the mean BMD value for young adults. Twenty consecutive patients with normal BMD (17 women, 3 men, aged 45 ±1 year, group A) were treated with high-dose intravenous MPPT (1 g per day DPD excretion compared with controls (TAbLEs 2 and 3).
Effect of simultaneous methylprednisolone pulse therapy and alendronate treatment on bone formation and resorption markers MPPT and concomitant alendronate therapy decreased the levels of bone formation markers (serum osteocalcin, PICP, bAP) and bone resorption markers (serum ICTP and CTX, DPD urinary excretion) (TAbLEs 2 and 3). dIsCussION The aim of the study was to estimate the effect of short-term intravenous MPPT with or without alendronate therapy on bone turnover markers in patients with an active and moderately severe form of GO and with normal or reduced BMD. In patients with GO, the BMD of the lumbar spine and femoral neck was measured by DEXA before therapy. This examination was not repeated after 4 weeks of MPPT because the precise estimation of BMD loss by DEXA is not possible in such a short period of time.
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In patients with GO, the levels of bone formation and resorption markers were higher than in control subjects. Increased levels of bone resorption and formation markers are considered to be an evidence of enhanced bone turnover. All study patients were euthyroid during the study and at least 4 months prior to MPPT. However, all patients had been treated for hyperthyroidism in the past. There were no differences between the groups in terms of sex and TSH, FT 4 , and FT 3 with normal distribution) or the Mann-Whitney test (for parameters with distribution deviations). Differences in the number of smokers between groups B and C and group A were analyzed using the χ 2 test. The P value less than 0.05 was considered statistically significant.
REsuLTs serum thyroid-stimulating hormone, free triiodothyronine, and free thyroxine levels Patients with GO did not show any statistically significant differences in serum TSH, FT 3 , and FT 4 levels compared with healthy subjects (TAbLE 1). markers of bone formation Patients with GO had significantly higher serum osteocalcin, PICP, and bAP levels than controls (TAbLE 2) . markers of bone resorption Serum ICTP levels were significantly higher in groups A and B compared with control subjects. In group C, serum CTX concentration and urinary DPD excretion was significantly higher than in controls. Serum Ca and P levels as well as urinary Ca excretion did not differ significantly between GO patients and the control group (TAbLE 3) .
Effect of methylprednisolone pulse therapy on bone formation and resprption markers MPPT significantly reduced serum osteocalcin, PICP, and ICTP levels and increased urinary Ca excretion. In group B, MPTT significantly increased urinary Values are presented as means ± standard error of the mean.
Group A: patients with normal T-score (-1 to +1 SD) treated with methylprednisolone pulse therapy; group B: patients with T-score <-1 SDs treated with methylprednisolone pulse therapy; group C: patients with T-score < -1 SDs treated with methylprednisolone and alendronate.
a P <0.001 vs. controls; b P <0.05; c P <0.01; d P <0.001: groups B and C vs. group A Abbreviations: BMD -bone mineral density, CAS -clinical activity score, FT 3 -free triiodothyronine, FT 4 -free thyroxine, TES -total eye score, SD -standard deviation, TRAbs -serum TSH-receptor antibodies, TSHthyroid-stimulating hormone have been expected despite clinical and biochemical euthyreosis lasting at least 4 months. In the present study, the assessment of bone turnover markers was repeated after MPPT (the cumulative dose was 8 g during 4 weeks). MPPT caused a decrease in some markers of bone formation (osteocalcin and PICP) in all patients. MPPT also increased some markers of bone resorption (urinary DPD excretion in group B and urinary Ca excretion in groups A and B). Osteocalcin and bAP levels are considered to reflect different aspects of osteoblastic function. The measurement of PICP provides direct information on the rate of synthesis of type I collagen. ICTP and DPD are considered to be the markers of different bone resorption phases. Urinary DPD excretion is thought to be a much more sensitive and reliable measure of bone resorption than levels. Outdoor activities and nutrition were similar in all patient groups, but in groups with decreased BMD (B and C), longer periods of hyperthyroidism and a greater number of smokers were found compared with group A with normal BMD. Decreased BMD in groups B and C could most likely be attributed to prolonged thyrotoxicosis and perhaps to smoking. It is known that thyroid hormones accelerate bone formation and resorption, with more influence on bone resprption.
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Bone turnover can be enhanced even in subclinical hyperthyroidism.
16 In overt hyperthyroidism, a correlation between clinical symptoms, thyroid hormone levels, and bone turnover markers has been observed. 17 Moreover, increased bone turnover may persist for at least 2 to 8 months following the treatment of hyperthyroidism.
18 Thus, increased bone turnover in our study group might Values are presented as means ± standard error of the mean.
a P <0.05 vs. control; + P <0.05 before vs. after treatment b P <0.01 vs. control; ++ P <0.01 before vs. after treatment c P <0.001 vs. control; +++ P <0.001 before vs. after treatment Abbreviations: Ca -calcium, Cr -creatinine, CTX -cross-linked C-terminal telopeptide of type I collagen, DPD -deoxypyridinoline, ICTPcarboxyterminal telopeptide of type I collagen, P -potassium short-term MPPT could prevent an increase of bone resorption in patients with low initial bone mass and other risk factors for osteoporosis. Finally, there is the question whether this short-term high-dose MPPT administration reduces BMD. BMD measurement after such a short treatment may be not insensitive enough to show significant differences. 14 Newer technologies, such as high resolution peripheral quantitative computed tomography or micromagnetic resonance imaging, could be more helpful in identifying individual fracture risk in patients on glucocorticoids. 31 Additionally, a direct relationship between BMD and fracture risk in glucocorticoid--induced osteoporosis has not been established 32 because fractures occur at higher BMD. 33 Repeated assessment of BMD after 6 months or 1 year was not possible in our study group because some of the patients were treated using different regimens, including short-term high-dose MPPT, chronic prednisone treatment, or a combination of prednisone treatment and radiotherapy.
In conclusion, a harmful effect of short-term MPPT on bone turnover (expressed as a decrease of bone formation and an increase of bone resorption) was observed in patients with GO and with normal or reduced BMD. Combined methylprednisolone and alendronate treatment in patients with decreased BMD may inhibit bone resorption caused by methylprednisolone. plasma ICTP concentrations. Serum ICTP may also be derived from newly synthesized collagen. 19 In our study, MPPT decreased the serum levels of ICTP both in patients with normal and reduced BMD. Impaired synthesis of type I collagen during MPPT might have caused a decrease in serum ICTP levels.
The decrease in some markers of bone formation and the increase in some markers of bone resorption observed in our study after MPPT confirm the already recognized harmful effect of glucocorticoids on bone metabolism. This effect depends mainly on their cumulative dose. 7 A dose of prednisone above 7. 5 mg daily given for at least 3 months (or equivalent doses of other steroids) was associated with an increased risk of bone loss. 20 The cumulative dose of methylprednisolone used in our study exceeded a corresponding prednisone dose of 7.5 mg daily. Although MPPT was administered only for 4 weeks, it caused significant disturbances in bone metabolism. Thus, our findings seem to be in line with other literature data on the limited safety of glucocorticoid use. 21 Inhibition of bone formation is considered to be the most significant effect of glucocorticoids on the bone. Recent studies have shown that glucocorticoids act directly on osteoblasts via the upregulation of the OPG/RANKL/RANK system. Glucocorticoids decrease osteoblast differentiation, increase osteoblast and osteocyte apoptosis, and inhibit osteoprotegerin expression. 22 Moreover, bone loss observed in the first phase of glucocorticoid therapy is caused by extension of the lifespan of preexisting osteoclasts. 23 Biochemical markers of bone turnover reflect the rate of bone formation and bone resorption in the whole body. Our findings confirm the results of other authors.
24,25
Simultaneous use of methylprednisolone and alendronate in patients with reduced BMD normalized urinary DPD excretion. Moreover, in patients treated with methylprednisolone and alendronate, urinary Ca excretion was not significantly increased, in contrast to patients treated only with methylprednisolone. In addition, methylprednisolone and alendronate therapy decreased bone resorption documented by a decrease in serum CTX levels. CTX is currently considered to be the most sensitive marker of bone resorption. 26 Our results indicate that alendronate is able to inhibit methylprednisolone-induced bone resorption in patients with GO and with reduced BMD. Alendronate inhibits osteoclast-mediated bone resorption, leading to osteoclast inactivity and apoptosis and bone turnover suppression. 27 The other mechanism of bisphosphonate action could be the stimulation of osteoblasts to produce osteoprotegerin, 28 which prevents osteoclastic bone resorption.
29 Since glucocorticoids inhibit osteoprotegerin production by osteoblasts,
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it seems that alendronate could inhibit the unfavorable effect of glucocorticoids on the bone. Our results suggest that alendronate use during
